Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer.

Abstract	Degarelix, approved in the USA in 2008, is a gonadotropin-releasing hormone antagonist, representing one of the latest additions to androgen deprivation therapy (ADT). ADT is used as first-line therapy for locally advanced or metastatic prostate cancer with the aim to reduce testosterone to castrate levels. Like other gonadotropin-releasing hormone-antagonists, degarelix treatment results in rapid decrease in luteinizing hormone, follicle-stimulating hormone and testosterone levels without the associated risk of flare. Using one registration trial for degarelix with leuprolide as the active control, a cost-effectiveness analysis with a Markov model and a 20-year time horizon found the incremental cost-effectiveness ratio for degarelix to be US$245/quality-adjusted life years. Degarelix provides a cost-effective treatment for ADT among patients with locally advanced prostate cancer.
Authors	Hind T Hatoum, E David Crawford, Sandy Kildegaard Nielsen, Swu-Jane Lin, Dennis C Marshall
Journal	Expert review of pharmacoeconomics & outcomes research (Expert Rev Pharmacoecon Outcomes Res) Vol. 13 Issue 2 Pg. 261-70 (Apr 2013) ISSN: 1744-8379 [Electronic] England
PMID	23570437 (Publication Type: Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References	Antineoplastic Agents, Hormonal Oligopeptides acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide Gonadotropin-Releasing Hormone Testosterone Luteinizing Hormone Follicle Stimulating Hormone Leuprolide
Topics	Aged Aged, 80 and over Antineoplastic Agents, Hormonal (economics, therapeutic use) Cost-Benefit Analysis Follicle Stimulating Hormone (metabolism) Gonadotropin-Releasing Hormone (antagonists & inhibitors) Humans Leuprolide (economics, therapeutic use) Luteinizing Hormone (metabolism) Male Markov Chains Oligopeptides (economics, therapeutic use) Prostatic Neoplasms (drug therapy, economics, pathology) Quality-Adjusted Life Years Testosterone (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!